Synthesis and Analysis of Contaminants in EMS-Related Tryptophan
Eosinophilia-Myalgia-Syndrome (EMS) has been linked to the ingestion of Tryptophan (Trp) manufactured by a single company containing more than 60 UV-detectable minor contaminants (Belongia et al., 1990). Hill et al. (1993) showed by statistical comparison of case and non-case associated lots that six of these contaminants can be associated with EMS: 1,1’-Ethylidenebis-L-tryptophan (1,1’-EBT) (Smith et al., 1991) and 3-(Phenylamino)alanine (PAA)(Toyo’oka et al., 1991, Goda et al., 1992) have already been structurally characterized and linked with the occurrence of EMS. 2-(3-indolylmethyl)-L-tryptophan (Peak 200) has been structurally determined by Möller et al. (1991). The structures of the remaining 3 EMS related contaminant peaks are still unknown (Hill et al., 1993). However there is still no animal model that establishes all features of EMS and there is still a lack of statistical significance for the association of EMS with 1,1’-EBT, Peak 200 (Philen et al., 1993) and PAA (Hill et al., 1993). That raises the possibility that the etiologic agent is still unknown because it could not be found by RP-HPLC and UV-detection. That is applicable, for example, for substances exhibiting little UV-response or coeluting with the large L-Trp peak (Hertzman et al., 1991).
KeywordsFermentation Bacillus Alanine Tryptophan Aniline
Unable to display preview. Download preview PDF.
- Belongia, E.A., Hedberg, C.W., Gleich, G.J., White, K.E., Mayeno, A.N., Loegering, D.A., Dunette, S.L., Pirie, PL., MacDonald, K.L., and Osterholm, M.T., 1990, An investigation of the cause of the eosinophilia- myalgia syndrome associated with tryptophan use, N. Engl. J. Med.323: 357.CrossRefGoogle Scholar
- Feiden, 1994, Monographic Tryptophan, Deutsche Apotheker Zeitung134: 3361.Google Scholar
- Goda, Y., Suzuki, J., Maitani, T., Yoshihira, K., Takeda, M., and Uchiyama, M., 1992, 3-Anilino-L-alanine, structural determination of UV-5, a contaminant in EMS-associated L-tryptophan samples, Chem. Pharm. Bull.40: 2236.Google Scholar
- Hertzman, P.A., Falk, H., Kilbourne, E.M., Page, S., and Shulman, L.E.,1991, The eosinophilia-myalgia syndrome: The Los Alamos conference, J. Rheumatol. 18:867.Google Scholar
- Müller, A., Busker, E., Günther, K., and Hoppe B., 1991. Characterization of byproducts in L-tryptophan, Bioforum14: 350.Google Scholar
- Philen, R.M., Hill, R.F. Jr., Flanders, W.D., Caudill, S.P., Needham, L., Sewell, L., Sampson, E.J., Falk, H., Kilbourne, E.M., and the Eosinophilia-Myalgia Studies of Oregon, New York, and New Mexico, 1993, Tryptophan contaminants associated with eosinophilia-myalgia syndrome, Am. J. of Epidemiol.138: 154.Google Scholar
- Savige, W.E., 1975, New oxidation products of tryptophan, Aust. J. Chem.28: 2275.Google Scholar
- Sakimoto, K. and Torigoe, Y., 1994, Study of mechanism of peak E substance formation in process for manufacture of L-tryptophan, in:L-Tryptophan Current Prospects in Medicine and Drug Safety, W. Kochen and H. Steinhart, eds.,Walter de Gruyter Berlin, New York.Google Scholar
- Smith, M.J., Mazzola, E.P., Farrell, T.J., Sphon, J.A., Page, S.W., Ashley, D., Sirimanne, S.R., Hill, R.H. Jr., and Needham, L.L., 1991, 1, rEthylidenebis(L-tryptophan), structure determination of contaminant “97” - implicated in the eosinophilia.myalgia syndrome (EMS), Tetrahedron Lett. 32:991.Google Scholar
- Toyo’oka, T., Yamazaki, T., Tanimoto, T, Sato, K., Sato, M., K., Toyoda, M., Ishibashi, M., Yoshihira, K., and Uchiyama, M., 1991, Characterization of contaminants in EMS-associated L-tryptophan samples by high-performance liquid chromatography, Chem. Pharm. Bull.39: 820.Google Scholar